Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

As the dust settles on a phase 3 announcement that added $45 billion to Moderna’s market cap, analysts have begun to ask a ...

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...

Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday, ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before ...

Moderna's melanoma mRNA vaccine had a major Phase 3 breakthrough. Here's what's next and when it could become available for skin cancer patients.

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...